Yesterday, a Director at Repligen (RGEN), Karen Dawes, sold shares of RGEN for $394.8K.
Following Karen Dawes’ last RGEN Sell transaction on May 15, 2018, the stock climbed by 50.9%.
See today’s analyst top recommended stocks >>
Based on Repligen’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $69.47 million and quarterly net profit of $3.6 million. In comparison, last year the company earned revenue of $51.94 million and had a net profit of $5.64 million. The company has a one-year high of $109.94 and a one-year low of $52.87. Currently, Repligen has an average volume of 358.34K.
The insider sentiment on Repligen has been positive according to 28 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Karen Dawes’ trades have generated a 43.7% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins).
